Mavengity Expands into B2B Research
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the Article8th Circuit ruling
4 storiesS-1 public filing
1 storyMaryland's ban takes effect Oct 1
1 storyNon-renewal notice deadline Oct 2
2 storiesPreliminary injunction briefs due Oct 5
The SEC says Meyer Global Management raised $18.5 million from nearly 100 investors across single-company pre-IPO funds, missed a $46,020 capital call that cost one fund its SpaceX stake, and diverted $686,636 from money owed to investors.
Temporary rules effective September 30 make the Treasury Secretary, not a parent, the party who elects to open a Trump account, and the first round of automatic enrollments begins October 1.
Judge William Orrick ended 23 years of federal oversight of the Oakland Police Department, handing authority over discipline and policy to a city commission that answered to no federal judge.
Two men are charged with running counterfeit Ozempic from Chinese suppliers into U.S. distributors, a scheme prosecutors say continued after the FDA seized fakes and warned the public.
The Justice Department asked the en banc court to shut down Judge James Boasberg's contempt investigation into the March 2025 deportation flights. Several judges treated the request as a claim that courts answer to the executive branch.
The White House accord asks frontier labs to build internal controls, hire outside auditors and report to their own boards, and leaves every operative word undefined.
Immix's registrational study of NXC-201 shows an 89 percent complete response rate in relapsed AL amyloidosis, and the company raised $125 million the same day to fund what comes next.
Z-basivarsen improved hand myotonia and function against a matched natural history cohort at 12 months, and the endpoint carrying its accelerated approval is the one that just failed for the field's biggest program.
Invivyd's Phase 3 study shows VYD2311 is better tolerated than an mRNA COVID vaccine, and the approval case it supports will rest on antibody levels rather than proof that the drug prevents illness.
Non-English intent signal is still under twenty percent of total volume industrywide, which means most platforms are seeing a fraction of the buying activity happening outside English language markets.
One vendor is explicitly competing on restraint, arguing that a plausible AI generated article that is subtly wrong is worse for a knowledge base than no article at all.
Forrester's own buyer guidance undercuts the AI pitch: providers are getting measurably more efficient, and there is little evidence yet that any of that efficiency is reaching customer pricing.
Forrester's guidance to buyers is blunt: having a data centre in the EU answers one sovereignty question out of four, and most vendor pitches stop at the first.
Forrester frames 2026's binding constraint as a workforce that cannot be trained fast enough, which makes this a services category built around people more than platforms.
Forrester's Q3 2026 Wave scores ten providers against twenty nine criteria, cutting the field's criteria count for the first time, while a vendor that owns its content finishes last equal.
Two of the category's most prominent independent players are now owned by the card networks they were supposed to route around.
Forrester's provider count nearly doubled in three years, and every other technology category in this series points at the same root cause: the software works and the organisation does not change.
Every reference customer for one vendor said they would buy again, which in PLM can mean genuine excellence or a customer base that has nowhere else to go once the evidence chain is built.
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the ArticleWith James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the Article